caution larry

Hi, I’m Kim! This site provides a little insight to my journey of being diagnosised with Remitting Relapsing Multiple Sclerosis on October 26th 2004. I review books and documentaries, post MS-related news, and share my photos.

Subscribe (RSS)

no larry

My bloglines



November 2004
December 2004
January 2005
February 2005
March 2005
April 2005
May 2005
June 2005
July 2005
August 2005
September 2005
October 2005
November 2005
December 2005
January 2006
February 2006
March 2006
April 2006
May 2006
June 2006
July 2006
August 2006
September 2006
October 2006
November 2006
December 2006
January 2007
February 2007
March 2007
April 2007
May 2007
June 2007
July 2007
August 2007
September 2007
October 2007
November 2007
December 2007
January 2008
February 2008
March 2008
April 2008
May 2008
June 2008
July 2008
August 2008
September 2008
October 2008
November 2008
December 2008
January 2009
February 2009
March 2009
April 2009
May 2009
June 2009
July 2009
August 2009
September 2009
October 2009
November 2009
December 2009
January 2010
February 2010
March 2010
May 2010
June 2010
July 2010
September 2010
November 2011


Thursday, October 23, 2008
The patients on alemtuzumab have an increase in brain volume, which means the brain is repairing itself
Whoa. This is some big news. A Leukemia drug thats letting the brain repair damage. Pretty cool. Although there seem to be some side effects that are a bit strange. Better to live with those side effects than what the MS will do over time though? Hmmm...

"Alemtuzumab works by destroying lymphocytes, a type of white blood cell. By shutting down this part of the immune system, the drug seems to block the damage to brain tissue that occurs in MS.

But three per cent of those taking alemtuzumab in the trial developed a life-threatening autoimmune condition.

During the trial, 20 per cent of those treated with alemtuzumab developed an over- or under-active thyroid gland.

Three per cent of those in the alemtuzumab group developed a low platelet count that increases vulnerability to bleeding — a complication that can be easily treated if recognized early, the researchers said, but that led to one death during the study.

"The data convincingly demonstrate that intensive immunosuppression can dramatically reduce the accumulation of new inflammatory lesions and focal [neuron] scarring and the rate of clinical relapse in patients with recent-onset multiple sclerosis," neurologist Dr. Stephen Hauser wrote in an editorial accompanying the study.

The findings highlight the value of very aggressive therapy at the beginning of the disease and helps medical researchers address the relationship between the inflammatory and degenerative phases of the disease, Hauser added.